Seno names Keane as CMO
Seno Medical Instruments, a developer of opto-acoustic cancer platform technology, has appointed William F. Keane, MD, as its chief medical officer (CMO).
In this capacity, Keane will focus on the clinical utilization of opto-acoustic imaging technology, moving the technology through clinical studies for use in the diagnosis and treatment of cancer, according to the San Antonio-based Seno.
Previously, the company said that he was CMO at Reliant Pharmaceuticals, which was acquired by GlaxoSmithKline, where he provided for the integration of the two organizations’ scientific and medical endeavors. He has served as vice president of U.S. medical and scientific affairs at Merck, and served as chairman of the department of medicine at Hennepin County Medical Center in Minneapolis, and vice-chairman of the department of medicine at the University of Minnesota in Minneapolis.
In this capacity, Keane will focus on the clinical utilization of opto-acoustic imaging technology, moving the technology through clinical studies for use in the diagnosis and treatment of cancer, according to the San Antonio-based Seno.
Previously, the company said that he was CMO at Reliant Pharmaceuticals, which was acquired by GlaxoSmithKline, where he provided for the integration of the two organizations’ scientific and medical endeavors. He has served as vice president of U.S. medical and scientific affairs at Merck, and served as chairman of the department of medicine at Hennepin County Medical Center in Minneapolis, and vice-chairman of the department of medicine at the University of Minnesota in Minneapolis.